Scynexis gets BARDA award worth up to $214 million for antifungal SCY-247
The contract, signed September 25, 2026, funds a Phase 2 trial and could carry SCY-247 through NDA filing if all options are exercised.
SEC filing
Latest
4 stories
Monday, September 28
Tuesday, September 22
SCYNEXIS names Steven K. Burke to board as ADPKD program advances
The clinical-stage biotech added a kidney disease drug development veteran to its board as it works toward a Phase 2 study of SCY-770.
SEC filing
Thursday, September 10
Scynexis names Sanjay Subramanian as CFO, replacing retiring Ivor Macleod
The clinical-stage biotech said Subramanian took over as principal financial officer on September 9, 2026, while Macleod stays on through October to help with the transition.
SEC filing